Loading…
ADC Therapeutics SA is projected to rise to $4.35 by 2027, a +27% move from its current price of $3.43. ADCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.34 | $3.43 | $3.52 | -0.01% |
| May 30 | $3.30 | $3.43 | $3.56 | -0.03% |
| May 31 | $3.27 | $3.43 | $3.59 | -0.04% |
| Jun 1 | $3.25 | $3.43 | $3.62 | -0.05% |
| Jun 2 | $3.23 | $3.43 | $3.64 | -0.07% |
| Jun 3 | $3.21 | $3.43 | $3.66 | -0.08% |
| Jun 4 | $3.19 | $3.43 | $3.68 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.19 | $3.43 | $3.68 | -0.09% |
| Week 2 | $3.10 | $3.42 | $3.78 | -0.19% |
| Week 3 | $3.03 | $3.42 | $3.86 | -0.28% |
| Week 4 | $2.97 | $3.42 | $3.93 | -0.37% |
| Week 5 | $2.92 | $3.41 | $3.99 | -0.46% |
| Week 6 | $2.87 | $3.41 | $4.05 | -0.56% |
| Week 7 | $2.83 | $3.41 | $4.10 | -0.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. The company is incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Its flagship product, ZYNLONTA, is a CD19-directed ADC that received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The company is seeking to expand ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2.
ADC Therapeutics SA (ADCT) is a healthcare company with a current price of $3.39 and a market capitalization of $431.18M. It is ranked 3153 in market cap terms among listed assets. The near-term price outlook is framed by a 30-day technical picture that shows bearish momentum, but the long-term forecast provides a path of upside through mid- and late decade.
The 30-day range spans from $2.84 to $4.04, and the stock sits between a support level of $3.14 and a resistance level of $4.38.
The forecast table indicates a gradual lift in average prices across years, starting with 2026 at an average of $3.39 and moving toward higher levels by 2030 ($4.94) and beyond, with notable upside by 2040 ($11.47) and 2050 ($20.66). These figures come with varying estimated returns on investment and bullish sentiment from 2027 onward, suggesting meaningful upside potential over the longer term.
A major floor 29.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.5% below — buyers have tended to step in here.
The nearest ceiling, 27.7% above — a clean break opens room to run.
A major ceiling 42.6% above — clearing it would confirm fresh momentum.
Key ADCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.39 | Buy | $3.40 | Buy |
| MA 10 | $3.34 | Buy | $3.41 | Buy |
| MA 20 | $3.51 | Sell | $3.50 | Sell |
| MA 50 | $3.76 | Sell | $3.70 | Sell |
| MA 100 | $3.85 | Sell | $3.78 | Sell |
| MA 200 | $3.82 | Sell | $3.65 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.05 | Neutral |
| Stoch RSI (14) | 84.29 | Sell |
| CCI (20) | -28.99 | Neutral |
| Williams %R (14) | -52.46 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.00 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 47.54 | Neutral |
| TRIX (15) | -0.59 | Sell |
| Awesome (5,34) | -0.32 | Sell |
| Ultimate (7,14,28) | 51.17 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 3.50 | Sell |
| ADX (14) | 20.90 | Sell |
| ATR (14) | 0.09 | Info |
The near-term technical picture is bearish, with an RSI of 40. The stock trades below both the 50-day and 200-day moving averages, which sit at $3.79 and $3.81, respectively. This places the price in a context of downward pressure in the short run.
A defined support at $3.14 and a resistance at $4.38 frame the 30-day trading window, which has carved a range from $2.84 to $4.04 in the last month. Expect additional volatility, with the stock’s behavior likely to hinge on ongoing news and how prices interact with the 50/200-day moving averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.14 | $3.43 | $5.13 | 0% | Neutral | |
| $3.46 | $4.35 | $5.78 | +27% | Bullish | |
| $3.65 | $4.71 | $6.49 | +37% | Bullish | |
| $3.80 | $5.01 | $7.10 | +46% | Bullish | |
| $3.88 | $5.22 | $7.56 | +52% | Bullish | |
| $4.12 | $5.64 | $8.35 | +65% | Bullish | |
| $4.59 | $6.39 | $9.64 | +86% | Bullish | |
| $5.46 | $7.73 | $11.85 | +125% | Bullish | |
| $5.87 | $8.43 | $13.13 | +146% | Bullish | |
| $5.90 | $8.59 | $13.57 | +150% | Bullish | |
| $8.09 | $12.56 | $21.06 | +266% | Bullish | |
| $13.27 | $23.02 | $42.16 | +571% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.14 | $3.43 | $4.03 | +0.00% |
| June 2026 | $2.90 | $3.40 | $4.08 | -0.93% |
| July 2026 | $2.86 | $3.39 | $4.12 | -0.28% |
| August 2026 | $2.99 | $3.56 | $4.37 | +4.96% |
| September 2026 | $3.08 | $3.69 | $4.57 | +3.72% |
| October 2026 | $3.09 | $3.72 | $4.64 | +0.79% |
| November 2026 | $3.19 | $3.85 | $4.84 | +3.52% |
| December 2026 | $3.34 | $4.05 | $5.13 | +5.30% |
Click any year to see its month-by-month ADCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADCT could reach as high as $5.13, with a base case around $3.43 and support toward $3.14 — roughly 0% from $3.43. A consolidation phase looks the most probable path here.
Expect ADCT to range from $3.46 to $5.78 through 2027. The $4.35 average target implies a +27% move from current prices. That is up +27% on the projected 2026 average. Momentum favours further upside here.
The ADCT price prediction for 2028 points to an average of $4.71 (low $3.65, high $6.49) — a potential gain of +37% on today's $3.43. Buyers look set to stay in control over this stretch.
In 2029, ADCT is projected to trade between $3.80 and $7.10, averaging $5.01 — a potential gain of +46% from today's $3.43. That is up +6% on the projected 2028 average. Momentum favours further upside here.
ADC Therapeutics SA's 2030 outlook centres on $5.22, within a $3.88 to $7.56 range. That is up +4% on the projected 2029 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ADCT could reach as high as $8.35, with a base case around $5.64 and support toward $4.12 — roughly +65% from $3.43. Momentum favours further upside here.
Expect ADCT to range from $4.59 to $9.64 through 2032. The $6.39 average target implies a +86% move from current prices. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The ADCT price prediction for 2033 points to an average of $7.73 (low $5.46, high $11.85) — a potential gain of +125% on today's $3.43. Momentum favours further upside here.
In 2034, ADCT is projected to trade between $5.87 and $13.13, averaging $8.43 — a potential gain of +146% from today's $3.43. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
ADC Therapeutics SA's 2035 outlook centres on $8.59, within a $5.90 to $13.57 range. That is up +2% on the projected 2034 average. That marks a +150% change versus current levels. Momentum favours further upside here.
By 2040, ADCT could reach as high as $21.06, with a base case around $12.56 and support toward $8.09 — roughly +266% from $3.43. Buyers look set to stay in control over this stretch.
Expect ADCT to range from $13.27 to $42.16 through 2050. The $23.02 average target implies a +571% move from current prices. That is up +83% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ADCT today (≈ 291.54519 ADCT) could be worth
$6,712.56
+$5,712.56 (+571%) by 2050 · US Dollar
Based on the average projected ADCT price of $23.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADCTwould be worth at today's price.
$1,000 invested in ADCT on May 27, 2025 (≈ 400 ADCT) would be worth
$1,372
+$372 (+37.2%) today · 1.37× · US Dollar
Based on a ADCT entry price of $2.5 vs. today's $3.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.24 | $1,058.64 | +5.9% |
| 1 month ago | $3.76 | $912.23 | -8.8% |
| 3 months ago | $4.13 | $830.51 | -16.9% |
| 6 months ago | $4.3 | $797.67 | -20.2% |
| 1 year ago | $2.5 | $1,372 | +37.2% |
| All time (5.0y) ago | $22.16 | $154.78 | -84.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADCT forecast.
Our base-case forecast reaches $6.90 around 2033.
Implied market cap at $6.90: $877.62M
Over the multi-year horizon, the outlook shows a bullish trajectory starting notably from 2027 with a 2027 average of $4.23 and a 2027 ROI of 24.8, followed by further gains in 2028 ($4.59; ROI 35.4) and 2029 ($4.84; ROI 42.9). By 2030, the average is $4.94 with ROI 45.9 and the trend continues higher through 2031 ($5.34; ROI 57.6) and 2032 ($5.98; ROI 76.5). The forecast extends to 2033 ($7.18; ROI 111.9) and 2034 ($7.89; ROI 132.7), culminating in 2035 ($7.96; ROI 134.7).
Looking further out, the projected average climbs to $11.47 in 2040 (ROI 238.5) and to $20.66 in 2050 (ROI 509.3), with a largely bullish sentiment attached to these later years. Key drivers cited by the forecast include expansion of ZYNLONTA into international markets and earlier lines of therapy, plus ongoing trials and pipeline progress. Risks include the inherent uncertainty of clinical development outcomes, regulatory developments, and the competitive landscape in oncology therapies.
These are estimates, not guarantees, and should be considered within the broader context of market dynamics, clinical results, and regulatory timelines.
Tap a question to reveal the answer.
The 2030 forecast lists an avg price of $4.94, with a min of $3.67 and a max of $7.19, and a ROI of 45.9; sentiment is BULLISH.
From 2027 onward the forecast is bullish with avg increases: 2027 avg $4.23, ROI 24.8; 2028 avg $4.59, ROI 35.4; 2029 avg $4.84, ROI 42.9; 2030 avg $4.94, ROI 45.9; 2026 is neutral with avg $3.39 and ROI 0.
Yes, the 2035 max forecast is $12.60 and the 2034 max is $12.31, so hitting $10 is within the forecast range.
The sentiment is BEARISH with RSI14 at 40. The SMA50 is $3.79 and the SMA200 is $3.81, with a support at $3.14 and resistance at $4.38. The 30-day range spans $2.84 to $4.04.
Current price is $3.39 and market cap is $431.18M.
ADC Therapeutics SA Community Discussion
0Share your ADC Therapeutics SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.